Literature DB >> 27823967

Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles.

Zhouyu Zhu1, Tao Yu1, Ying Chai1.   

Abstract

We present a case of multiple primary lung cancer(MPLC) displaying heterogeneous EGFR and PTEN molecular profiles. Considering the physical condition of patients, the patient underwent surgical resection of the right lung lesion displaying gefitinib-insensitive and continued gefitinib treatment for the gefitinib-sensitive lesions in the left lung. As far as we know, this is the first report documenting a case of an integrated therapy strategy using surgical resection with gefitinib treatment for MPLC displaying different EGFR and PTEN molecular profiles. The patient has been in progression free survival up to now. Our experience could provide a treatment strategy for patients with similar disease.

Entities:  

Keywords:  EGFR; PTEN; gefitinib; multiple primary lung cancer

Mesh:

Substances:

Year:  2016        PMID: 27823967      PMCID: PMC5348444          DOI: 10.18632/oncotarget.13046

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  6 in total

1.  The results of modern surgical therapy for multiple primary lung cancers.

Authors:  S A Adebonojo; D M Moritz; C A Danby
Journal:  Chest       Date:  1997-09       Impact factor: 9.410

2.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

3.  Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.

Authors:  Teruhisa Takuwa; Fumihiro Tanaka; Kazue Yoneda; Ikuko Torii; Masaki Hashimoto; Yoshitomo Okumura; Seiji Matsumoto; Nobuyuki Kondo; Seiki Hasegawa
Journal:  Lung Cancer       Date:  2010-03-21       Impact factor: 5.705

4.  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

Authors:  Martin L Sos; Mirjam Koker; Barbara A Weir; Stefanie Heynck; Rosalia Rabinovsky; Thomas Zander; Jens M Seeger; Jonathan Weiss; Florian Fischer; Peter Frommolt; Kathrin Michel; Martin Peifer; Craig Mermel; Luc Girard; Michael Peyton; Adi F Gazdar; John D Minna; Levi A Garraway; Hamid Kashkar; William Pao; Matthew Meyerson; Roman K Thomas
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

5.  Clinical and molecular analysis of synchronous double lung cancers.

Authors:  Junichi Arai; Tomoshi Tsuchiya; Masahiro Oikawa; Koji Mochinaga; Tomayoshi Hayashi; Koh-Ichiro Yoshiura; Kazuhiro Tsukamoto; Naoya Yamasaki; Keitaro Matsumoto; Takuro Miyazaki; Takeshi Nagayasu
Journal:  Lung Cancer       Date:  2012-05-03       Impact factor: 5.705

Review 6.  Epidermal growth factor receptor mutations in lung adenocarcinoma.

Authors:  Markus D Siegelin; Alain C Borczuk
Journal:  Lab Invest       Date:  2013-12-30       Impact factor: 5.662

  6 in total
  5 in total

1.  Overexpression of PTEN suppresses non-small-cell lung carcinoma metastasis through inhibition of integrin αVβ6 signaling.

Authors:  Yan Xia Yu; Yi Wang; Hong Liu
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Zinc finger RNA-binding protein promotes non-small-cell carcinoma growth and tumor metastasis by targeting the Notch signaling pathway.

Authors:  Heng Zhang; Chun Fang Zhang; Ri Chen
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

3.  Molecular biological analysis in a patient with multiple lung adenocarcinomas.

Authors:  Tomoshige Wakayama; Hirokuni Hirata; Shunsuke Suka; Kozo Sato; Masamitsu Tatewaki; Ryosuke Souma; Hideyuki Satoh; Motohiko Tamura; Yuji Matsumura; Hiroki Imada; Kumiya Sugiyama; Masafumi Arima; Kazuhiro Kurasawa; Takeshi Fukuda; Yasutsugu Fukushima
Journal:  Thorac Cancer       Date:  2018-03-26       Impact factor: 3.500

Review 4.  PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around.

Authors:  Anastasios Gkountakos; Giulia Sartori; Italia Falcone; Geny Piro; Ludovica Ciuffreda; Carmine Carbone; Giampaolo Tortora; Aldo Scarpa; Emilio Bria; Michele Milella; Rafael Rosell; Vincenzo Corbo; Sara Pilotto
Journal:  Cancers (Basel)       Date:  2019-08-09       Impact factor: 6.639

5.  Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.

Authors:  Bo Jin; Simeng Zhang; Xin Chuang; Ping Yu; Ying Chen; Yuee Teng; Xiaofang Che; Yibo Fan; Chunlei Zheng; Xiaohan Li; Xueshan Qiu; Xiujuan Qu; Yunpeng Liu
Journal:  BMC Cancer       Date:  2018-11-20       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.